1.Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM et al.. (2014) Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold.. J Med Chem, 57 (8):(3418-29). [PMID:24678969]
2.Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW et al.. (2016) Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.. Pharmacol Res Perspect, 4 (6):(e00275). [PMID:28097008]
3.Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M et al.. (2016) A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.. Neuropsychopharmacology, 41 (7):(1803-12). [PMID:26585287]
4.Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O'Malley SS, Wong CJ. (2016) Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.. Alcohol Clin Exp Res, 40 (9):(1935-44). [PMID:27435979]
5.Witkin JM, Wallace TL, Martin WJ. (2019) Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).. Handb Exp Pharmacol, 254 (3):(399-415). [PMID:30701317]
6.Ferrari F, Rizzo S, Ruzza C, Calo G. (2020) Detailed In Vitro Pharmacological Characterization of the Clinically Viable Nociceptin/Orphanin FQ Peptide Receptor Antagonist BTRX-246040.. J Pharmacol Exp Ther, 373 (1):(34-43). [PMID:31937563]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
